Dividend Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.99 USD | +0.08% |
|
+1.33% | +9.78% |
EPS & Dividend: Charles River Laboratories International, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.2 | 7.6 | 9.48 | 9.22 | 0.2 | 4.193 | 7.245 | 9.219 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Reference price 2 | 247.17 | 371.96 | 215.04 | 238.78 | 186.16 | 218.99 | 218.99 | 218.99 |
| Nbr of stocks (in thousands) | 49,743 | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 49,215 | - |
| Announcement Date | 17/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | 19/02/25 | - | - | - |
1USD in Million2USD
Estimates
Upcoming events: Charles River Laboratories International, Inc.
| 18/02/2026 | Q4 2025 Earnings Release (Projected) |
| 07/05/2026 | Q1 2026 Earnings Release (Projected) |
| 12/08/2026 | Q2 2026 Earnings Release (Projected) |
| 11/11/2026 | Q3 2026 Earnings Release (Projected) |
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | 52.22x | 3.06x | 3.17x | |
| 0.88% | 1% | 38.98x | 4.01x | 5.66x | |
| -.--% | -.--% | 34.02x | 6.48x | 3.37x | |
| -.--% | -.--% | 107.41x | 9.71x | 6.89x | |
| 0.33% | 0.34% | 58.35x | 2.79x | 11.95x | |
| -.--% | -.--% | -21.47x | 14.61x | 6231.22x | |
| - | - | - | - | - | |
| -.--% | -.--% | 41.11x | 41.04x | 6.66x | |
| 0.85% | 0.93% | 28.5x | 2.46x | 2.26x | |
| -.--% | -.--% | 27.2x | 1.5x | 2.11x | |
| Average | 0.23% | 0.25% | 40.70x | 9.52x | 697.03x | |
| Weighted average by Cap. | 0.28% | 0.31% | 45.36x | 8.54x | 602.41x |
Year-on-year evolution of the Yield
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition